Galectin Therapeutics (GALT) Operating Income (2010 - 2026)

Galectin Therapeutics' Operating Income history runs 17 years deep, the most recent figure standing at -$4.1 million for Q1 2026.

• In Q1 2026, Operating Income rose 48.37% year-over-year to -$4.1 million; the TTM figure through Mar 2026 stood at -$16.3 million (up 60.02% YoY), while the FY2025 annual figure was -$20.1 million, up 52.67% from the prior year.
• Operating Income was -$4.1 million for Q1 2026 at Galectin Therapeutics, down from -$3.4 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$3.4 million in Q4 2025 to a low of -$12.4 million in Q4 2024.
• Historically, Operating Income has averaged -$8.4 million across 5 years, with a median of -$9.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Operating Income tumbled 57.27% in 2022, then surged 72.92% in 2025.
• A 5-year view of Operating Income shows it stood at -$10.6 million in 2022, then increased by 10.08% to -$9.6 million in 2023, then declined by 29.99% to -$12.4 million in 2024, then soared by 72.92% to -$3.4 million in 2025, then dropped by 21.16% to -$4.1 million in 2026.
• The last three Operating Income figures came in at -$4.1 million (Q1 2026), -$3.4 million (Q4 2025), and -$4.2 million (Q3 2025), per Business Quant data.